David Friedman

About David Friedman

David Friedman

Professor and Director of The Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, MD, USA

David is known for his contributions to the study of the mechanisms, epidemiology and prevention of angle-closure glaucoma. He has also made contributions in the area of medication adherence and was the principal investigator in the first trial to show that an intervention can successfully improve patient use of eye medicines. David has received various awards, co-edited a definitive book on angle-closure glaucoma, and published nearly 150 articles.

What have been your career highlights?

“Directing a team of researchers trying to determine best practices in managing blinding eye diseases in less developed countries including trachoma, diabetic retinopathy and refractive error. Being elected to the Glaucoma Research Society (limited to the top 100 researchers globally in glaucoma) and to the Alcon Research Institute (which selects the six best researchers in all of ophthalmology each year). Finally, being listed as a Best Doctor many years in a row.”

What’s the future of glaucoma management?

“We will move to more remote monitoring of care and will increasingly have access to more effective treatments. Blindness rates will be greatly reduced.”